Similar articles

• Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.

  Bozkurt O, de Boer A, Grobbee DE, Kroon AA, Schiffers P, de Leeuw P, Klungel OH. Bozkurt O, et al. J Renin Angiotensin Aldosterone Syst. 2009 Jun;10(2):101-8. doi: 10.1177/1470320309104877. J Renin Angiotensin Aldosterone Syst. 2009. PMID: 19502258
• The antihypertensive effect of peptides: a novel alternative to drugs?

  Hong F, Ming L, Yi S, Zhanxia L, Yongquan W, Chi L. Hong F, et al. Peptides. 2008 Jun;29(6):1062-71. doi: 10.1016/j.peptides.2008.02.005. Epub 2008 Feb 16. Peptides. 2008. PMID: 18384915 Review.
• [Experimental rationale for local use of angiotensin-converting enzyme inhibitors for the treatment of ocular tissue ischemia on a model of postburn conjunctival ischemia].

  Chesnokova NB, Kost OA, Nikol'skaia II, Beznos OV, Binevskiĭ PV, Makarov PV, Stoliarova EP, Pavlenko TA. Chesnokova NB, et al. Vestn Oftalmol. 2008 Jul-Aug;124(4):28-31. Vestn Oftalmol. 2008. PMID: 18756797 Russian.
• Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.

  Gotsman I, Rubonivich S, Azaz-Livshits T. Gotsman I, et al. Isr Med Assoc J. 2008 Mar;10(3):214-8. Isr Med Assoc J. 2008. PMID: 18494235
• The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease.

  Brugts JJ, den Uil CA, Danser AH, Boersma E. Brugts JJ, et al. Cardiology. 2009;112(4):303-12. doi: 10.1159/000159124. Epub 2008 Oct 2. Cardiology. 2009. PMID: 18832826 Review.